Atlas Trials

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

Clinical trial NCT05297617 · RECRUITING

Trial details

NCT number
NCT05297617
Sponsor
UNICANCER
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2022-10-12
Primary completion
2030-11-12
Enrollment
696

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.